NPM1 mutations are considered as most persistent mutations that take place in 25 to 35% of AML patients.47, 48These mutations are answerable for confined NPM1 protein in the cytoplasmic section of the cell. The gene discussed is NPM1; the disease is acute myeloid leukemia.